After 18 months of suffering from diarrhea, John Thomas turned to a remedy with a major "yuck" factor: a fecal transplant, in which "good" bacteria from a donor's feces are delivered into the colon to kill "bad" bacteria.
Regulatory News:
This hospital had no heart — but the jury sure did! A prestigious Manhattan hospital got smacked by a Queens jury, which awarded $2.35 million to the family of hard-working dad of three Ronald Bello, who died in agony shortly after he received a disea…
Twelve-month-old Llana Qazi was diagnosed last October and then kept alive by five different mechanical hearts because doctors in Tyneside could not keep her stable.
A drug that stops the body from rejecting bone marrow transplants could soon be ready for human trial.
Alnylam Pharmaceuticals Inc. released top-line results from its phase 2b trial for its treatment of respiratory syncytial virus, an infection in lung transplant patients. The Cambridge company said the trial was a randomized, double-blind, placebo-cont…
SEATTLE , May 31, 2012 /PRNewswire/ — Cell Therapeutics, Inc.("CTI") (Nasdaq and MTA: CTIC) today announced that results from its PIX301 phase 3 clinical trial of Pixuvri® (pixantrone) have …
Doctors in Newcastle are leading the way in transplant technology. The scientists at Newcastle University have developed a technique of washing lungs to make more donor organs useable. After successful trials at the Freeman Hospital the method is now b…
(Reuters) – Alnylam Pharmaceuticals Inc's experimental drug to treat a type of respiratory infection in lung transplant patients missed the main goal of a mid-stage trial. The drug, codenamed ALN-RSV01, is being developed to treat respiratory syncy…
Alnylam Pharmaceuticals Reveal Positive Results Of Phase IIb Trial Of ALN-RSV01